Download PDF
Horm Metab Res 1986; 18(10): 704-705
DOI: 10.1055/s-2007-1012411
Clinical

© Georg Thieme Verlag, Stuttgart · New York

Evidence for Increased Endogenous Dopaminergic Inhibition of Aldosterone Secretion in Prolactinoma

E. Jungmann1 , U. Schwedes2 , P.-H. Althoff1 , C. Rosak1 , K. Schöffling1
  • 1Zentrum der Inneren Medizin, Abteilung für Endokrinologie des Klinikums der Johann Wolfgang Goethe-Universität, Frankfurt am Main
  • 2II. Medizinische Klinik des Klinikums Mannheim der Universität Heidelberg, Mannheim, Germany
Further Information

Publication History

1985

1985

Publication Date:
14 March 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Aldosterone responsiveness to consecutive i.v. injections of metoclopramide 1 mg, 2.5 mg and 10 mg was studied in 8 patients with prolactinoma and normally preserved adrenal function and in 14 healthy volunteers. In the patients, aldosterone response to metoclopramide 1 mg was blunted. After metoclopramide 10 mg, aldosterone rose to the same levels in patients and volunteers. In the patients, however, percentage rise of aldosterone was enhanced, since the appropriate base line concentration of aldosterone was decreased. Thus, there is evidence for increased endogenous dopaminergic inhibition of aldosterone secretion in prolactinoma.

Key-Words

Prolactinoma - Aldosterone - Dopamine

      >